PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies, including treatments targeting COVID-19 and other infectious diseases. The company entered the public markets through a merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Capital, which completed its SPAC IPO in 2021; the de-SPAC transaction closed in early 2022. The company filed the referenced 8-K with the SEC on June 5, 2023, reflecting ongoing corporate reporting obligations as a post-combination public entity operating in the biopharmaceutical sector. Sign up on SpacDesk for full filing history, deal metrics, and real-time alerts on PRDS and hundreds of other SPAC transactions.